Share on StockTwits

Mednax (NYSE:MD) COO Joseph M. Calabro sold 150,000 shares of Mednax stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $55.55, for a total transaction of $8,332,500.00. Following the transaction, the chief operating officer now directly owns 226,542 shares of the company’s stock, valued at approximately $12,584,408. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Mednax (NYSE:MD) traded up 1.81% on Monday, hitting $56.30. The stock had a trading volume of 713,233 shares. Mednax has a 1-year low of $41.825 and a 1-year high of $56.445. The stock has a 50-day moving average of $53.95 and a 200-day moving average of $52.33. The company has a market cap of $5.691 billion and a price-to-earnings ratio of 19.91.

Mednax (NYSE:MD) last issued its quarterly earnings data on Thursday, January 30th. The company reported $0.20 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.75 by $0.55. The company had revenue of $567.00 million for the quarter, compared to the consensus estimate of $555.30 million. Analysts expect that Mednax will post $3.15 EPS for the current fiscal year.

Separately, analysts at KeyCorp initiated coverage on shares of Mednax in a research note to investors on Tuesday, December 17th. They set a “hold” rating on the stock. Eight analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Mednax presently has a consensus rating of “Hold” and an average target price of $106.57.

MEDNAX, Inc (NYSE:MD) is a provider of physician services, including newborn, maternal-fetal, pediatric subspecialties and anesthesia care.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.